BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 23067221)

  • 1. Bevacizumab in combination with chemotherapy in the first-line treatment of metastatic colorectal carcinoma.
    Usakova V; Sevcikova K; Usak J; Bartosova Z; Mikulova M; Spanik S
    Neoplasma; 2013; 60(1):83-91. PubMed ID: 23067221
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Practical use of capecitabine plus oxaliplatin (CAPEOX) with bevacizumab for patients with metastatic colorectal cancer that cannot expect conversion therapy.
    Yokomizo H; Yoshimatsu K; Otani T; Osawa G; Nakayama M; Matsumoto A; Yano Y; Okayama S; Naritaka Y
    Hepatogastroenterology; 2013; 60(128):1911-5. PubMed ID: 24719926
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Adjuvant systemic chemotherapy with or without bevacizumab in patients with resected liver metastases from colorectal cancer.
    Turan N; Benekli M; Koca D; Ustaalioglu BO; Dane F; Ozdemir N; Ulas A; Oztop I; Gumus M; Ozturk MA; Berk V; Kucukoner M; Uner A; Balakan O; Helvaci K; Ozkan S; Yilmaz U; Buyukberber S;
    Oncology; 2013; 84(1):14-21. PubMed ID: 23076023
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Specific treatment situations in metastatic colorectal cancer].
    Arnold D; Schmoll HJ; Lang H; Knoefel WT; Ridwelski K; Trarbach T; Staib L; Kirchner T; Geissler M; Seufferlein T; Amthauer H; Riess H; Schlitt HJ; Piso P
    Onkologie; 2010; 33 Suppl 4():8-18. PubMed ID: 20431307
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Addition of Bevacizumab to First-Line Chemotherapy for Metastatic Colorectal Cancer.
    Tsutsumi S; Fujii T; Yamaguchi S; Suto T; Yajima R; Morita H; Kato T; Asao T; Kuwano H
    Hepatogastroenterology; 2014 May; 61(131):633-7. PubMed ID: 26176048
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Outcome and natural history of patients with stage IV colorectal cancer receiving chemotherapy without primary tumor resection.
    Nitzkorski JR; Farma JM; Watson JC; Siripurapu V; Zhu F; Matteotti RS; Sigurdson ER
    Ann Surg Oncol; 2012 Feb; 19(2):379-83. PubMed ID: 21861213
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Usefulness of monthly chemotherapy for patients with unresectable metastatic colorectal cancer.
    Tomoda M; Kawahara H; Watanabe K; Enomoto H; Akiba T; Yanaga K
    Anticancer Res; 2014 Jan; 34(1):191-4. PubMed ID: 24403461
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bevacizumab-associated fistula formation in postoperative colorectal cancer patients.
    Ganapathi AM; Westmoreland T; Tyler D; Mantyh CR
    J Am Coll Surg; 2012 Apr; 214(4):582-8; discussion 588-90. PubMed ID: 22321523
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Capecitabine and oxaliplatin (XELOX) as first-line treatment for patients with metastatic colorectal cancer.
    Karacetin D; Yalcin B; Okten B; Ozturk S; Maral O; Incekara O
    J BUON; 2009; 14(4):605-8. PubMed ID: 20148449
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Surgical resection of hepatic and pulmonary metastases from colorectal carcinoma.
    Shah SA; Haddad R; Al-Sukhni W; Kim RD; Greig PD; Grant DR; Taylor BR; Langer B; Gallinger S; Wei AC
    J Am Coll Surg; 2006 Mar; 202(3):468-75. PubMed ID: 16500252
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical outcomes associated with bevacizumab-containing treatment of metastatic colorectal cancer: the BRiTE observational cohort study.
    Kozloff M; Yood MU; Berlin J; Flynn PJ; Kabbinavar FF; Purdie DM; Ashby MA; Dong W; Sugrue MM; Grothey A;
    Oncologist; 2009 Sep; 14(9):862-70. PubMed ID: 19726453
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Predictive value of optimal morphologic response to first-line chemotherapy in patients with colorectal liver metastases.
    Yoshita H; Hosokawa A; Ueda A; Ando T; Kajiura S; Kato H; Kawabe H; Tomizawa G; Horikawa N; Yabuhita K; Note M; Sugiyama T
    Digestion; 2014; 89(1):43-8. PubMed ID: 24458112
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cediranib with mFOLFOX6 versus bevacizumab with mFOLFOX6 as first-line treatment for patients with advanced colorectal cancer: a double-blind, randomized phase III study (HORIZON III).
    Schmoll HJ; Cunningham D; Sobrero A; Karapetis CS; Rougier P; Koski SL; Kocakova I; Bondarenko I; Bodoky G; Mainwaring P; Salazar R; Barker P; Mookerjee B; Robertson J; Van Cutsem E
    J Clin Oncol; 2012 Oct; 30(29):3588-95. PubMed ID: 22965961
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Risk factors for the requirement of surgical or endoscopic interventions during chemotherapy in patients with uncomplicated colorectal cancer and unresectable synchronous metastases.
    Yun JA; Park Y; Huh JW; Cho YB; Yun SH; Kim HC; Lee WY; Chun HK
    J Surg Oncol; 2014 Dec; 110(7):839-44. PubMed ID: 25043872
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Survival outcomes of bevacizumab beyond progression in metastatic colorectal cancer patients treated in US community oncology.
    Cartwright TH; Yim YM; Yu E; Chung H; Halm M; Forsyth M
    Clin Colorectal Cancer; 2012 Dec; 11(4):238-46. PubMed ID: 22658457
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Thromboembolic events in patients with colorectal cancer receiving the combination of bevacizumab-based chemotherapy and erythropoietin stimulating agents.
    Roddy JV; Partridge SM; Rockey ML; Pruemer JM; Guo JJ; Desai SJ; Safa MM
    Am J Clin Oncol; 2010 Feb; 33(1):36-42. PubMed ID: 19652579
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pathologic response to bevacizumab-containing chemotherapy in patients with colorectal liver metastases and its correlation with survival.
    Gruenberger T; Arnold D; Rubbia-Brandt L
    Surg Oncol; 2012 Dec; 21(4):309-15. PubMed ID: 22884035
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Survival for metastatic colorectal cancer in the bevacizumab era: a population-based analysis.
    Renouf DJ; Lim HJ; Speers C; Villa D; Gill S; Blanke CD; O'Reilly SE; Kennecke H
    Clin Colorectal Cancer; 2011 Jun; 10(2):97-101. PubMed ID: 21859560
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bevacizumab beyond first progression is associated with prolonged overall survival in metastatic colorectal cancer: results from a large observational cohort study (BRiTE).
    Grothey A; Sugrue MM; Purdie DM; Dong W; Sargent D; Hedrick E; Kozloff M
    J Clin Oncol; 2008 Nov; 26(33):5326-34. PubMed ID: 18854571
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The use of high dose d,l-leucovorin in first-line bevacizumab+mFOLFIRI treatment of patients with metastatic colorectal cancer may enhance the antiangiogenic effect of bevacizumab.
    Budai B; Nagy T; Láng I; Hitre E
    Angiogenesis; 2013 Jan; 16(1):113-21. PubMed ID: 22956187
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.